Introduction {#sec1-1}
============

A person\'s environment, diet and overall health can influence how s/he responds to medicines. Genes are another factor which determining a person\'s response to drugs. Pharmacogenetics aims to understand the role of a person\'s genetic make-up play in the good effects and side-effects of a medicine in a person\'s body. A thorough knowledge of this will lead to a future where tailor-made drugs, suited for an individual, can be used.

Concurrently, wide usage of Pharmacogentics is seen in the Scandinavians Countries and the most widely used application is for genotyping CYP2D6 when treating psychiatric illness.

Genetic variation contributes to inter-patient differences in drug response. Such variations may occur for drug metabolism, drug transporter and drug target proteins. Most of the variations occurring in the human genome are single nucleotide polymorphism (SNPs) with an occurrence rate of at least one every 1000 base pairs. Genetic Polymorphism may cause an alteration in the efficacy of a drug or its toxicity.

Genes contain instructions for making proteins, including proteins which interact with drugs. Any change in a gene can result in changes in the associated protein involved i.e, an enzyme of dug metabolism. Individuals get one copy of a gene from each parent, but each of those copies may have a change or mutation. Mutation can result in production of an enzyme with reduced function or no enzyme may be produced at all. Depending on whether a Person has 0, 1 or 2 normal copies of genes, he or she may be grouped as poor, intermediate or rapid metabolizer. The less normal copies a person has, the poorer the metabolism, and hence, higher blood levels of the drug. This may result in greater effectiveness or more likely greater side effects.

History {#sec1-2}
=======

Looking back, the first pharmacogentics trait to be observed was --- \"taste blindness\" to a chemical called Phenylthiourea (PTU). Individuals with a certain gene profile were unable to taste PTU, while others could.This hereditary chemical insensitivity led researchers to understand the genetic differences between races. Mankind has known genetic sensitivity to various substances since time immemorial which can be corroborated by the fact that susceptibility to alcohol by certain ethnic groups was well known 100 years ago. The concept Pharmacogentics began in the 1950s, nearly by chance, as a result of isolating genetic differences in metabolizing rugs. Numerous findings provided an early stimulus for the development of Pharmacogentics For example, the inheritance of phase I reaction impairment studied on Succinylcholine (Muscle Relaxant). Since the 1950s, novel technologies have been combined with a new genetic approach to decipher variation at person to person level.

Pharmacogentics has been broadly applied in the study and treatment of cancers. A classical case of Pharamacogentics in oncology happened way back in 1988, when the Journal on Clinical Investigation reported the case of a 40-year-old woman being treated for breast cancer. The woman almost died from a standard done of chemothera \[autic agent\] since she possessed a genetic defect due to which she was unable to metabolize the drug. Pharmacogentics played a major role in understanding the cause and led to an entirely new approach to treatment. Till date, it is widely known that reaction to cancer treatment can very widely from patient from patient to patient.\[[@CIT1]\]

Pharmacokinetic Variations {#sec1-3}
==========================

Drug metabolism {#sec2-1}
---------------

Metabolism usually converts drug to metabolites which are more water soluble and thus more easily excreted. It can also convert products into therapeutically active compounds and may even result in the formation of toxic metabolites.

Pathway of drug metabolism is classified as:

phase I reaction (Oxidation, Reduction, hydrolyis)phase II reaction (Acetylation, glucuronidation, Methylation etc).

The above said nomenclature is histamical which means that phase II reaction can precede phase I reaction and often can occur without oxidation,reduction, hydrolysis.

However, both the reactions often convert lipid soluble drugs into relatively more water-soluble metabolites. These fundamental reactions of drug metabolism are impacted by the individual\'s genetic Information. Approximately 1 in 3500 white people code for an atypical form of enzyme butyl cholinesterase which is relatively unable to hydrolyze succinylcholine (muscle relaxant) thereby prolonging drug induced muscle paralysis and resultant apnoea. Similarly it has been observed that common genetic variations in phase II reactions e.g. Acetylation can result in objectionable differences in the half life and plasma Concentration of drugs metabolized by N-acetyltransferase e.g. Isoniazid, Hydralazine and Procainamide. These variations in Acetylation has clinical consequences. The Cytochrome P-450 enzyme, a super family of microsomal drug metabolizing enzymes, is the most important of enzymes which catalyze phase I drug metabolism reactions.

One member of this family, CYP2D6 (cytochrome P-450 2D6), has been the most intensively studied and is the best example of Pharmacogenetic variation in drug metabolism. The CYP2D6 genetic polymorphism was originally discovered as a result of striking difference in the pharmacokinetics and therapeutic effects of drugs metabolized by this enzyme. Drugs as diverse as codeine, dextromethophan, metaprolol and tryptyline are all metabolized by this enzyme. CYP2D6 is needed to break down the drug and eliminate it. People who have low levels of enzymes metabolize drugs slowly and the drug will remain in the body for a longer period of time than it was metabolized quickly. Slow metabolizers are more likely to hace side effects. Moreover, people who produce low levels of CYP2D6 in liver will need smaller doses of drug hat are eliminated by this enzymes, while fast metabolizers i.e. people who have high levels of enzyme will need larger drug dose to get the same effect, by applying molecular genetic technique, 75

CYP2D6 alleles have been described. This CYP2D6 polymorphism is an excellent example of potential clinical implications of pharmacogentics. In some cases, the differences in drug responses can be correlated to ethnic background Noteworthy is the variation in Drug Metabolism enyzme in various ethnic groups \[[Table 1](#T0001){ref-type="table"}\].\[[@CIT2]\]

###### 

Classifi cation of various families of CYP ISO-enzyme

  Isoenzymes                                                                                                                                                             Substrates                                                                                                                                                                                                                                                                                 Inducers                                     Inhibitors                                                                                                                                                                                                                                                                                                                                   Effects
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CYP2A6                                                                                                                                                                 Nicotines, 5-hydroxy coumarins                                                                                                                                                                                                                                                             Not inducible                                ?                                                                                                                                                                                                                                                                                                                                            Inactive (1-3% of Caucasians) inactive (deletions common in Asians)
  CYP2B6                                                                                                                                                                 Artemisinin, S-mephobarbital, S-ifosfamide, cyclophosphamide coumarin activation                                                                                                                                                                                                           Phenobarbital, cyclophosphamide              Not inducible                                                                                                                                                                                                                                                                                                                                {Used in retroviral vector gene Rx of cancer!} expression in early childhood is poor
  CYP2C8                                                                                                                                                                 TCA, diazepam (found in kidney, adrenal,brain, uterus, breast, ovary and duodenum), verapamil                                                                                                                                                                                              Rifampicin, phenobarbitone                   Cimetidine                                                                                                                                                                                                                                                                                                                                   Expression in early childhood is poor
  CYP2C9                                                                                                                                                                 S-warfarin, phenytoin, diclofenac and other NSAIDS, tolbutamide, fluoxetine, torsemide, verapamil, dextromethorphan                                                                                                                                                                        Rifampicin, carbamazepine, ethanol           Fluconazole, ketoconazole, sulphonamides (sulfaphenazole), sulphinpyrazone, amiodarone, ritonavir, metronidazole minimal effect                                                                                                                                                                                                              Less active. phenytoin toxicity
  CYP2C18                                                                                                                                                                (Found in brain, uterus, breast, kidney and duodenum; liver levels \~10% of those of 2C8 and 2C9)                                                                                                                                                                                          Phenobarbitone, artemisinin (?)              Sulfaphenazole, fluoxetine, omeprazole, ritonavir, fluvoxamine, oral contraceptives ticlopidine                                                                                                                                                                                                                                              Similar to 2C19; metabolizes cyclophosphamide, ifosfamide, verapamil, lansoprazole
  CYP2C19                                                                                                                                                                (Found in duodenum but few other extrahepatic tissues; lower hepatic expression than 2C9) (S) mephenytoin, phenytoin, diazepam, TCA (clomipramine, imipramine..), dextromethorphan, propranolol, omeprazole, progesterone, sertraline, aminopyrine                                         Phenobarbitone, artemisinin.                 Sulfaphenazole, fluoxetine, omeprazole, ritonavir, fluvoxamine, oral contraceptives ticlopidine                                                                                                                                                                                                                                              Inactive (in up to 20% of Asians,3% of Caucasians, 19% of African Americans, 8% of Africans, up to 71% of Paciflc islanders, Low activity allows dual Rx of *H pylori* with good success! Low B12 with long term omeprazole Rx! risk of phenytoin toxicity
  CYP2D6 \"debrisoquine hydroxylase\" (about 2% of liver CYP, the only active 2D in man {rats have \~six!}) found mainly in the liver, with LITTLE intestinal activity   Debrisoquine, dextromethorphan, beta blockers, haloperidol, chlorpromazine, thioridazine dexfenfluramine, flecainide, propafenone, mexiletine, procainamide fentanyl, pethidine {=meperidine}, SSRIs (fluoxetine), TCAs, trazadone, zuclopenthixol, S-mianserin, tolterodine; azelastine   Not inducible                                cimetidine { \>\>\> ranitidine }, quini\[di\]ne, methadone, SSRIs Some TCAs (paroxetine fluoxetine norfluoxetine sertraline desmethylsertraline fluvoxamine, nefazodone, venlafaxine clomipramine amitriptyline), Antipsychotics (perphenazine thioridazine chlorpromazine haloperidol fluphenazine risperidone clozapine cis-thiothixine)   Common in Chinese, common in Black Africans, 10% of Caucasians are poor metabolisers;
  CYP2E1 (about 7% of liver CYP)                                                                                                                                         Paracetamol {=acetaminophen}, ethanol pentobarbitone, tolbutamide, propranolol, rifampicin, Coumarin activation, Many volatile anesthetics: Isoflurane, sevoflurane, enflurane                                                                                                             Chronic ethanol intake, isoniazid, benzene   Disulflram, (cimetidine) (acute ethanol intake!)                                                                                                                                                                                                                                                                                             Association with alcoholic liver disease, liver cancer, lung and nasopharyngeal cancer (cigarettes) (Chinese polymorphism)

Pharmacodynamic Variations {#sec1-4}
==========================

Drug response {#sec2-2}
-------------

Genetic variations in drug target, e.g., receptors have a profound effect on drug efficacy.

The response to 12- agonists is affected by genetic polymorphism of 12-adrenoceptor (coded by ADRB2 gene). Three single nucleotide polymorphism in ADBR2 have been associated with altered expression, down regulates or Coupling of the receptor in response to 12-receptor agonists. In some individuals it has been noticed that a dose up to 20 times greater than normal may be required to produce the desired anticoagulant effect by Warfarin. The reduced activity of Warfarin is attributed to a genetically controlled reduction in binding affinity of Warfarin receptor.\[[@CIT3]\]

A life threatening malignant hyper thermis affects about one in 20,000 patients. This disorder causes a fatal elevation in body temp and is consequent to a hyper-metabolic response to a combination of a depolarizing muscle relaxant (SuccinylCholine) and a Potent Volatile inhalational General Anaesthetic (Halothane). The susceptibilty to the disorder (inherited in an autosomal dominant pattern) is due to mutation in the gene that encodes the ryanodine receptor (Calcium release channel).

ACE-inhibitor improves symptoms of survival in case of heart failure in Caucasians as compared to African-Americans. This implies that a genetic screening of individuals might be allowed to apply this knowledge in clinical practice. Certain drugs act by binding to specific chemicals called receptors sites on the surface of our body within body cells. Variation in those genes that code for receptors means that same people may produce receptors that do not interact well with the drug, for example. Some people do not respond to the bronchodilator Salbutamol as they show genetic variation in the gene those codes for a receptor on surface of S.M cellular lining the bronchial airways.

Drug Development {#sec1-5}
================

A sound knowledge of the genetic make-up of an individual can be of importance in drug treatments trials. In Alzheimer disease which affects 25% of people in older age group of over 85, the gene associated is called APOE. This gene occurs in three forms known as E2, E3 and E4. All three have the same primary function to produce an essential protein called apoliprotein E is split of contain slightly different information this protein modifies the development of Alzheimer disease by interfering with the production of a brain cortex and the ceels deteriorate. The most common form of gene is E3. The E4 from gene is Supposed be associated with Alzheimer disease and the same is also distinctly involved in drug treatment for Alzheimer diseases. Individuals with Alzheimer disease who have E2 and E3 from of APOE gene respond well to the drug Tacrine (r), while those with E4 do not.\[[@CIT4]\]

Ethical issues {#sec2-3}
--------------

The idea of targeting certain groups within population can be a touching subject, no matter how well intentioned, as in the case of targeting sickle cell anaemia screening in early 1970\'s to the American black population without appropriate knowledge. Such programs, if conceptualized, have to be carefully implemented to avoid a perception of stigma based or ethnicity. Moreover, questions might be raised on the assumptions that a person\'s race can indicate their genetic profile for drug response since all the people belonging to a particular ethnic group will not have the same genetic variations. Consequently, genetic profiling may culminate into denial of treatment to a certain ethnic group race if a Pharmacogenetic test that could determine more precisely how a person\'s reaction, was not available.

Merits {#sec2-4}
------

Drugs may be developed targeting specific health problems that will maximize therapeutic effects but not decrease healthy cells.The likely hard of adverse effects might be reduced by having an idea of the drug to be used based on genetic profiling.Better vaccines made of genetic material having all the benefits of existing vaccines but with reduced risk of infections.The likelihood of over-dosage may be less if dosage were based on a persons genetic makeup rather than a body weight or agePharmacogenetics can be used in testing for reaction to is environmental toxins. This finds reference in today\'s times. Since many areas have high carcinogenic agents individuals susceptible to safe place for them to live a normal, healthy life.Revival of older drugs e.g. Clozapine where agranulocytes in 0.5 to 2% of patients limits the use of this agent as first therapy for Schizophrenia despite its proven efficacy.

Results and Discussion {#sec1-6}
======================

In some cases, the differences in drug responses can be correlated to ethnic background Noteworthy is the variation in drug metabolism enzyme in various ethnic groups \[[Table 2](#T0002){ref-type="table"}\].\[[@CIT5]\]

###### 

The Variation in drug metabolism enzyme in various ethnic groups

  Drug                                                      Enzyme                                  Population                                             Effect
  --------------------------------------------------------- --------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------
  Sulfonamide, Chloramphenicol                              Glucose-6-Phospate Dehydrogenase        Black males                                            Acute Haemolysis in different people
  Nitrofurantoin                                                                                                                                           
  Nalixidic acid                                                                                                                                           
  Perhexiline (Antianginal)                                 CYP2D6                                  Asian, African                                         Neuropathy in poor metabolizers
  TCA (Desipramine and nortryptyline)                       CYP2D6                                                                                         Inadequate anti-depressant response in ultra rapid metabolisers
  Antipsychotic (Haloperidol)                               CYP2D6                                  East Asians                                            Increase in plasma conc. and exagg. Response in intermediate metabolizers
  Codeine, Tramadol (prodrugs)                              CYP2D6                                  6-8% Swedens 1% Chinese(PM\'s)                         Decrease in analgesic effect in poor metabolizers
  Enalapril                                                 CYP2D6                                  Blacks                                                 
  Prozac(Flouxitine)                                        CYP2D6                                  Black(PM\'s)                                           Likely to have more side effects (nausea,insomnia,terry headache)
  Antiviral drug (ter.hep.C)                                                                        African-American                                       Do not respond well
  (Alpha interferon and ribavarin)                                                                                                                         
  Narcotics                                                                                         Asians more sensitive                                  Apnea
  Debrisoquin                                               CYP2D6                                  10% of whites inN. America and Europe                  Orthostatic hypotension
  5-FU                                                      Dihyropyrimide                                                                                 Fatal increase drug effect, N.S. toxicity
                                                            Dehydrogenase                                                                                  
  Isoniazid                                                 Rapid Acetylation                       East Asian                                             
                                                            Slow Acetylation                        Asian and Eskimos                                      
  Warfarin                                                  CYP2C9                                  Caucasian                                              Anti-coagulation (due to inactive variant if gene)
  Omeprazole                                                CYP2C19                                 14.6% Chinese 18% Japanese                             Improved cureratis for *H. Pylori* in poor metabolizers
  Ethanol                                                   Aldehyde Dehydrogenase                  50% Japanese Chinese Asian                             Facial Fluhing increased heart rate diaphoresis due to lack of enzyme
  **Biological anomalies in different population groups**                                                                                                  
  **Factor**                                                **Population**                          **Effect**                                             
                                                                                                                                                           
  Heavy salivation                                          Blacks                                  Intubations diffcult, drying agents given              
  Low K + Levels                                            Asian Males                             Temporary paralysis                                    
  Sickle cell anaemia                                       Africans and Medite                                                                            
  Likely multiple                                           Caucasian                                                                                      
  Cystic Fibrosis                                           Caucasian                                                                                      
  More likely to have nitric oxide in sufficiency           Black                                                                                          
  Lack Aldehyde                                             50% Japanese, Chinese and other Asian   Facial flushing, increase heart rate and diaphoresis   
  G-6PD defi ciency                                         10% Black males                         Hemolytic anemia                                       
  CYP2D6                                                    7% Caucasian                            Poor Metabolism                                        
  Decrease HDL and Increase TG                              Indians                                                                                        

Conclusion {#sec1-7}
==========

The ramification of Pharmacogentics is the ability to screen potential adverse reactions.

Technological advances in the way of human genome project (completed in April 2003) will finally allow us to tailor drug therapies to each patient and move beyond \'race\' as a crude indicator or genetic variations.

Genetic finger printing of an individual is already practical. This can determine the presence of polymorphism in genes and an individualized care can be given in future. Studies to correlate DNA finger prints with data present in medical records about medical history and drug response can be undertaken. These studies will have a deep impact on the ways in which new drugs are developed and used. Such programs, if conceptualized, have to be carefully implemented to avoid a perception of stigma based or ethnicity. Moreover, questions might be raised on the assumptions that a person/race can indicate their genetic profile for drug response since all the people belonging to a particular ethnic group will not have the same genetic variations. Consequently, genetic profiling may culminate into denial of treatment to a certain ethnic group/race if a Pharmacogenetic test that could determine more precisely how a person reacts was not available.
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